Foresight Capital Management Advisors Inc. Purchases 11,774 Shares of Bristol Myers Squibb Company $BMY

Foresight Capital Management Advisors Inc. grew its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 32.4% during the 2nd quarter, HoldingsChannel reports. The firm owned 48,144 shares of the biopharmaceutical company’s stock after acquiring an additional 11,774 shares during the quarter. Foresight Capital Management Advisors Inc.’s holdings in Bristol Myers Squibb were worth $2,774,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in BMY. Trust Point Inc. boosted its stake in Bristol Myers Squibb by 51.8% during the 2nd quarter. Trust Point Inc. now owns 13,912 shares of the biopharmaceutical company’s stock valued at $802,000 after purchasing an additional 4,748 shares during the period. Castle Rock Wealth Management LLC increased its position in Bristol Myers Squibb by 3.2% in the 2nd quarter. Castle Rock Wealth Management LLC now owns 47,869 shares of the biopharmaceutical company’s stock worth $2,702,000 after buying an additional 1,506 shares during the period. Elevation Wealth Partners LLC lifted its holdings in shares of Bristol Myers Squibb by 22.5% during the second quarter. Elevation Wealth Partners LLC now owns 1,417 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 260 shares during the last quarter. Czech National Bank lifted its holdings in shares of Bristol Myers Squibb by 4.8% during the second quarter. Czech National Bank now owns 581,252 shares of the biopharmaceutical company’s stock worth $33,492,000 after buying an additional 26,627 shares during the last quarter. Finally, PensionDanmark Pensionsforsikringsaktieselskab boosted its position in shares of Bristol Myers Squibb by 7.6% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 545,224 shares of the biopharmaceutical company’s stock valued at $31,416,000 after acquiring an additional 38,596 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.7%

Shares of Bristol Myers Squibb stock opened at $64.63 on Friday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.10. The firm has a market capitalization of $132.02 billion, a PE ratio of 14.24, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The company’s fifty day moving average price is $58.71 and its two-hundred day moving average price is $58.64.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period last year, the firm earned $1.46 EPS. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.96 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades improve sentiment. Argus upgraded BMY to Buy, while Zacks raised the stock to a Rank #2 (Buy), citing improving earnings prospects. These recommendations may attract additional income- and value-oriented investors. Argus Upgrades Bristol Myers Squibb to Buy Bristol Myers Moves to Buy
• Positive Sentiment: Recent earnings exceeded expectations. Bristol Myers Squibb reported quarterly earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue of $12.97 billion surpassed the $11.74 billion forecast. Revenue also grew 5.7% year over year, reinforcing the positive earnings narrative discussed on the company’s earnings call. Bristol Myers Squibb Q2 Earnings Call
• Positive Sentiment: Pipeline and research investments provide longer-term support. BMY is launching a real-world study examining luspatercept use in anemia care, while an expanded partnership with Schrödinger will deploy AI drug-discovery tools across BMS teams. These initiatives could improve evidence generation and help accelerate future medicines. Bristol Myers Squibb Tracks Luspatercept Use Schrödinger and BMS Expand Partnership
• Neutral Sentiment: Broader optimism around potential biotech and pharmaceutical catalysts may support sector sentiment, but the cited drug-development opportunities are not specific to BMY. New Drugs Could Fuel Pharma Stock Gains

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Guggenheim restated a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Raymond James Financial started coverage on shares of Bristol Myers Squibb in a research note on Wednesday. They set a “strong-buy” rating for the company. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Roth Capital began coverage on shares of Bristol Myers Squibb in a report on Wednesday. They set a “buy” rating and a $75.00 price objective on the stock. Finally, Bank of America cut their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.